| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 Feb 2025 | 4 Feb 2025 |
| SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve 1.Approval of Standalone Unaudited Financial Results for Q ended 31st December 2024 2. any other matter with permission of chairman Appointment of the Internal Auditor for the FY 2025-26 (As Per BSE Announcement Dated on 13/02/2025) | ||
| Board Meeting | 14 Nov 2024 | 4 Nov 2024 |
| SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve approval of standalone and consolidated unaudited financials results for quarter and half year ended 30.09.2024 outcome of the Board Meeting dated 14th November 2024 (As Per BSE Announcement Dated on 14.11.2024) Corrigendum to the Outcome of the Board Meeting held on 14th November 2024 (As Per BSE Announcement Dated on 15.11.2024) | ||
| Board Meeting | 12 Aug 2024 | 3 Aug 2024 |
| SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 inter alia to consider and approve 1. To Approve Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter ended 30th June 2024. 2. To Consider and appoint Shri. Vijay Kottapalli (DIN: 10245156) as Additional Director (Non Executive Independent Director) of the Company. 3. To consider/recommend Dividend for the Financial Year 2023-24. Outcome of the Board Meeting dated 12th August 2024 (As Per BSE Announcement Dated on 12.08.2024) | ||
| Board Meeting | 5 Jun 2024 | 31 May 2024 |
| SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/06/2024 inter alia to consider and approve 1. Approval of Standalone and Consolidated Financials for the Q and Year ended 31.03.2024 2.Any other matter with permission of the Chairman Audited Results (Revised) (As Per Bulletin Dated on: 30/05/2024 Outcome of the Board Meeting Audited Financial Results for the year ended 31.03.2024 (As Per BSE Announcement Dated on: 05/06/2024) | ||
| Board Meeting | 30 May 2024 | 20 May 2024 |
| SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve 1. To Approve Standalone and Consolidated Audited Financial Results of the Company for the Quarter and Year ended 31st March 2024 2. To Consider and Reappoint CMA Shekhar Joshi & Co Cost Accountants (Registration No. 100448) as Cost Auditor of the Company for the Financial Year 2024-25. 3. Any other matter with the permission of Chairman. Outcome of the Board Meeting dated 30th May 2024 (As Per BSE Announcement Dated on: 30/05/2024) Audited Results (Revised) Outcome of the Board Meeting dated 30th May 2024 (As Per Bulletin Dated on: 30/05/2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
